{"id":"W2023078169","doi":"10.1002/ibd.21896","title":"Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study","year":2011,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":207,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; London Health Sciences Centre","funders":"Takeda Oncology","keywords":"Vedolizumab; Ulcerative colitis; Medicine; Tolerability; Pharmacokinetics; Pharmacodynamics; Internal medicine; Gastroenterology; Crohn's disease; Pharmacology; Adverse effect; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003909115,0.0004577158,0.0009492268,0.00009845524,0.0002912008,0.00003631003,0.0003141469,0.0001040994,0.0001108349],"category_scores_gemma":[0.0004890059,0.0002996446,0.001095738,0.00005952754,0.0004567854,0.0000200492,0.00005148268,0.00004889059,0.00000801844],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006535282,"about_ca_system_score_gemma":0.000386582,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003014002,"about_ca_topic_score_gemma":0.0001069952,"domain_scores_codex":[0.9973515,0.00067252,0.0007972821,0.0004966459,0.0002624997,0.000419583],"domain_scores_gemma":[0.9978096,0.0003929773,0.0004990336,0.0007199101,0.0003604947,0.0002179299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9791625,0.004419917,0.002572694,0.00007078229,0.004151541,0.0001880101,0.004821732,0.0000651462,0.0006875979,0.0005702613,0.0001815865,0.003108217],"study_design_scores_gemma":[0.8068789,0.00204512,0.1767611,0.00004145524,0.003179571,0.000004245054,0.004392839,0.0007738252,0.004285925,0.0003339988,0.0007345125,0.0005685277],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98628,0.0009510006,0.0003687293,0.00001291854,0.0002864881,0.01097559,0.0005122158,0.00004797796,0.0005650815],"genre_scores_gemma":[0.9908062,0.0001786019,0.00005171463,0.00005466908,0.0003239035,0.008126443,0.00008971788,0.00005897182,0.0003097937],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1741884,"threshold_uncertainty_score":0.9999456,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01539788876544992,"score_gpt":0.2767287282332005,"score_spread":0.2613308394677506,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}